Predictions
Incyte Corp.
Start price
Target price
Perf. (%)
€72.06
20.12.20
20.12.20
-
20.12.21
20.12.21
-7.02%
21.02.21
21.02.21
Revenue growth >5% per year expected
EBIT growth >5% per year expected
Dependend from some customers or products
Gilead Sciences Inc
Start price
Target price
Perf. (%)
€48.01
18.12.20
18.12.20
€45.00
-1.78%
23.12.20
23.12.20
Known brand
Fair valuation
Leading role in innovation
Future proof or reliable business model
Gilead Sciences Inc
Start price
Target price
Perf. (%)
€48.17
18.12.20
18.12.20
€27.00
18.06.21
18.06.21
14.83%
19.01.21
19.01.21
Top 10 in its market
Good rating
Medium risks for its business
Bad culture
Pfizer Inc.
Start price
Target price
Perf. (%)
€31.01
18.12.20
18.12.20
€34.00
18.12.21
18.12.21
-5.35%
15.03.21
15.03.21
Small challenges to pay loans and raise capital
Innovative
Very small cyclical dependencies
Some uniques
Pfizer Inc.
Start price
Target price
Perf. (%)
€30.91
17.12.20
17.12.20
€29.00
-1.81%
21.12.20
21.12.20
Capable Management
Good culture
Innovative
Differentiated customer and product portfolio
Alexion Pharmaceutical Inc.
Start price
Target price
Perf. (%)
€142.00
13.12.20
13.12.20
€170.00
13.12.21
13.12.21
9.00%
14.12.21
14.12.21
Could be worthwhile Investment >10% per year
Revenue growth >5% per year expected
EBIT growth >5% per year expected
Higher EBIT margin than peer group
Regeneron Pharmaceuticals Inc.
Start price
Target price
Perf. (%)
€395.05
12.12.20
12.12.20
-
12.12.21
12.12.21
4.78%
09.01.21
09.01.21
Known brand
Could be worthwhile Investment >10% per year
Future proof or reliable business model
Top 10 in its market
Pfizer Inc.
Start price
Target price
Perf. (%)
€35.01
12.12.20
12.12.20
-
12.12.21
12.12.21
-14.23%
24.03.21
24.03.21
Revenue growth >5% per year expected
Stable Large shareholder and/or long term investor
Could be worthwhile Investment >10% per year
Significant cyclical dependencies
Regeneron Pharmaceuticals Inc.
Start price
Target price
Perf. (%)
€392.75
11.12.20
11.12.20
€250.00
0.97%
11.12.20
11.12.20
Known brand
Could be worthwhile Investment >10% per year
Future proof or reliable business model
Top 10 in its market
Pfizer Inc.
Start price
Target price
Perf. (%)
€31.50
30.11.20
30.11.20
€38.00
30.11.21
30.11.21
18.40%
02.08.21
02.08.21
Could be worthwhile Investment >10% per year
Very high dividend yield expected
Fair valuation
Higher EBIT margin than peer group
Regeneron Pharmaceuticals Inc.
Start price
Target price
Perf. (%)
€442.80
23.11.20
23.11.20
€555.00
23.11.21
23.11.21
29.97%
24.11.21
24.11.21
Revenue growth >5% per year expected
EBIT growth >5% per year expected
Fair valuation
Standard Investments for future growth
Regeneron Pharmaceuticals Inc.
Start price
Target price
Perf. (%)
€485.05
23.11.20
23.11.20
€770.00
07.07.23
07.07.23
39.47%
25.05.23
25.05.23
Could be worthwhile Investment >10% per year
Revenue growth >5% per year expected
EBIT growth >5% per year expected
ROE higher than 15% per year
Regeneron Pharmaceuticals Inc.
Start price
Target price
Perf. (%)
€529.00
22.11.20
22.11.20
€450.00
-25.76%
11.12.20
11.12.20
Known brand
Could be worthwhile Investment >10% per year
Future proof or reliable business model
Top 10 in its market
Regeneron Pharmaceuticals Inc.
Start price
Target price
Perf. (%)
€529.00
22.11.20
22.11.20
€500.00
22.11.21
22.11.21
7.75%
23.11.21
23.11.21
Regeneron Pharmaceuticals Inc.
Start price
Target price
Perf. (%)
€437.60
19.11.20
19.11.20
€426.00
19.11.21
19.11.21
1.19%
23.11.20
23.11.20
Revenue growth >5% per year expected
EBIT growth >5% per year expected
Fair valuation
Standard Investments for future growth
Pfizer Inc.
Start price
Target price
Perf. (%)
€31.40
18.11.20
18.11.20
-
18.11.21
18.11.21
45.06%
19.11.21
19.11.21
EBIT growth >5% per year expected
Higher EBIT margin than peer group
Fair valuation
Low dividend yield expected
Gilead Sciences Inc
Start price
Target price
Perf. (%)
€51.30
14.11.20
14.11.20
-
14.11.21
14.11.21
-1.75%
23.11.20
23.11.20
Known brand
Fair valuation
Leading role in innovation
Future proof or reliable business model
Gilead Sciences Inc
Start price
Target price
Perf. (%)
€50.60
13.11.20
13.11.20
€52.00
1.38%
14.11.20
14.11.20
Known brand
Fair valuation
Leading role in innovation
Future proof or reliable business model
Gilead Sciences Inc
Start price
Target price
Perf. (%)
€50.00
09.11.20
09.11.20
€55.00
2.66%
10.11.20
10.11.20
Known brand
Fair valuation
Leading role in innovation
Future proof or reliable business model
Pfizer Inc.
Start price
Target price
Perf. (%)
€33.30
09.11.20
09.11.20
€37.95
-11.94%
17.12.20
17.12.20
Capable Management
Good culture
Innovative
Differentiated customer and product portfolio
Gilead Sciences Inc
Start price
Target price
Perf. (%)
€49.75
31.10.20
31.10.20
-
04.11.21
04.11.21
0.53%
09.11.20
09.11.20
Known brand
Fair valuation
Leading role in innovation
Future proof or reliable business model
Gilead Sciences Inc
Start price
Target price
Perf. (%)
€51.03
24.10.20
24.10.20
€58.00
04.11.21
04.11.21
-0.20%
11.11.20
11.11.20
Medium risks for its business
Risky Investment
Gilead Sciences Inc
Start price
Target price
Perf. (%)
€54.61
23.10.20
23.10.20
€55.00
31.10.20
31.10.20
-8.91%
31.10.20
31.10.20
Known brand
Fair valuation
Leading role in innovation
Future proof or reliable business model
Vertex Pharmaceuticals Inc.
Start price
Target price
Perf. (%)
€177.98
22.10.20
22.10.20
€170.00
04.11.21
04.11.21
-6.03%
05.11.21
05.11.21
Could be very worthwhile Investment >20% year
Revenue growth >5% per year expected
EBIT growth >5% per year expected
Rising EBIT margin expected